Reblozyl
Reblozyl ingredients
| Active ingredient | Strength |
|---|---|
| Luspatercept | 75 mg/1, 25 mg/1 |
What Reblozyl is used for
The FDA lists the approved uses on the official label (below). In the EU, luspatercept is approved as Reblozyl for:
Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia. Reblozyl is indicated in adults for the treatment of transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Reblozyl
- Generic name
- Luspatercept
- Made by
- Celgene Corporation
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Subcutaneous
- Drug class
- Erythroid Maturation Agent
- FDA approval
- Biologic licence (BLA) BLA761136
- On the US market since
- 2019
Official information
- Reblozyl prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Luspatercept)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Reblozyl?
Reblozyl (Luspatercept) is a specialist medicine made by Celgene Corporation, approved by the US FDA.
What are the ingredients of Reblozyl?
Reblozyl contains Luspatercept (75 mg/1, 25 mg/1).
Is Reblozyl approved in Europe?
The same active substance is approved in the EU as Reblozyl.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA